deltatrials
Completed NA INTERVENTIONAL 2-arm NCT03011268

Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? (BIOSTOP)

Continuing or Discontinuing Anti-tumor Necrosis Factor Treatment in Patients With Ulcerative Colitis in Clinical Remission: a Prospective Open Randomized Parallel-group Study

Sponsor: Helse Møre og Romsdal HF

Conditions Colitis,Ulcerative
Interventions Continuation of anti-TNF treatment Discontinuation of anti-TNF treatment
Updated 16 times since 2017 Last updated: May 27, 2025 Started: Jun 9, 2017 Primary completion: Jan 20, 2025 Completion: Jan 20, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Colitis,Ulcerative and is currently completed. Helse Møre og Romsdal HF leads this study, which shows 16 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jan 2018 · 4 months · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Feb 2019 · 6 months · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Oct 2020 · 13 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Apr 2023 · 7 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed NA

  2. Jun 2025 — Sep 2025 [monthly]

    Completed NA

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting NA

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting NA

  5. Apr 2023 — Jul 2024 [monthly]

    Active Not Recruiting NA

▶ Show 11 earlier versions

  1. Sep 2022 — Apr 2023 [monthly]

    Active Not Recruiting NA

  2. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting NA

    Status: Recruiting → Active Not Recruiting

  3. Jan 2021 — Sep 2021 [monthly]

    Recruiting NA

  4. Oct 2020 — Jan 2021 [monthly]

    Recruiting NA

  5. Sep 2019 — Oct 2020 [monthly]

    Recruiting NA

  6. Feb 2019 — Sep 2019 [monthly]

    Recruiting NA

  7. Aug 2018 — Feb 2019 [monthly]

    Recruiting NA

  8. Jun 2018 — Aug 2018 [monthly]

    Recruiting NA

  9. Jan 2018 — Jun 2018 [monthly]

    Recruiting NA

  10. Sep 2017 — Jan 2018 [monthly]

    Recruiting NA

    Status: Not Yet Recruiting → Recruiting · Phase: PHASE4 → NA

  11. Feb 2017 — Sep 2017 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helse Møre og Romsdal HF
  • Oslo University Hospital
  • University of Oslo
Data source: Helse Møre og Romsdal HF

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bergen, Norway , Fredrikstad, Norway , Førde, Norway , Hamar, Norway , Harstad, Norway , Kristiansand, Norway , Kristiansund, Norway , Levanger, Norway , Lørenskog, Norway , Oslo, Norway and 7 more locations